IP Library Granted Patent US 8,753,645
Granted Patent B2
US 8,753,645 · App. 13/581,824 · Granted Jun 17, 2014

Conjugation process of bacterial polysaccharides to carrier proteins

Inventors: Ralph Leon Biemans (Rixensart, BE); Pierre Duvivier (Rixensart, BE); Ollivier Francis Nicolas Gavard (Rixensart, BE)
Assignee: GlaxoSmithKline Biologicals S.A.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,753,645
App. No.
13/581,824
Granted
Jun 17, 2014
Kind
B2
Abstract

Process for conjugation of bacterial saccharides including Streptococcus pneumoniae and Haemophilus influenzae saccharides by reductive amination are provided herein.

Claims (15)

1. A process for conjugating a bacterial saccharide and reducing the sizing effect on bacterial saccharide comprising the steps of

a) reacting the bacterial saccharide with 0.001-0.7 molar equivalents of periodate to form an activated bacterial saccharide,

b) mixing the activated bacterial saccharide with a carrier protein;

c) reacting the activated bacterial saccharide and the carrier protein with a reducing agent to form a conjugate;

wherein step a) occurs in a buffer which does not contain an amine group, and the buffer has a concentration between 1-100 mM and wherein the bacterial saccharide is S.pneumoniae capsular saccharide 23F.

2. The process of claim 1 wherein the buffer is selected from the group consisting of phosphate buffer, borate buffer, acetate buffer, carbonate buffer and citrate buffer.

3. The process of claim 1 wherein the pH in step a) is pH 3.5-8.0.

4. The process of claim 1 wherein the average molecular weight of the bacterial saccharide is between 1-1100 kDa after step a).

5. The process of claim 1 wherein the average molecular weight of the 23F saccharide is between 100-470 kDa after step a).

6. The process of claim 1 wherein the carrier protein is selected from the group consisting of tetanus toxoid, fragment C of tetanus toxoid, diphtheria toxoid, CRM197, Pneumolysin, protein D, PhtD, PhtDE and N19.

7. The process of claim 1 wherein the reducing agent comprises sodium cyanoborohydride or sodium triacetoxyborohydride.

8. The process of claim 1 comprising a further step e) of purifying the conjugate.

9. The process of claim 1 containing a further step of mixing the conjugate with further antigens.

10. The process of claim 9 wherein the further antigens comprise one or more S.pneumoniae proteins selected from the group consisting of the Poly Histidine Triad family (PhtX), Choline Binding Protein family (CbpX), CbpX truncates, LytX family, LytX truncates, CbpX truncate-LytX truncate chimeric proteins (or fusions), pneumolysin (Ply), PspA, PsaA, Sp128, Sp101, Sp130, Sp125 and Sp133.

11. The process of claim 1 wherein the conjugate is mixed with an adjuvant or a pharmaceutically acceptable excipient.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 14, 2013
From: BIEMANS, RALPH LEON; DUVIVIER, PIERRE; GAVARD, OLLIVIER FRANCIS NICOLAS
To: GLAXOSMITHKLINE BIOLOGICALS S.A.
Reel/Frame 029621/0072 →
Priority Claims (1)
GB 1003922.0 · Mar 9, 2010 · national
Continuity (1)
Related Publication 20120321660A1 · Dec 20, 2012